Replies to post #48113 on Biotech Values

[rfj1862]

Hi ghmm,

I am not in ALTU right now as I sold shortly after I purchased it because I felt that AIS at $1.15 had more near-term upside potential, so I ended up buying a lot more.

I agree that ALTU is a very promising company. It remains a little expensive (market cap $405M), but they do have plenty of cash in the bank and, as you noted, upcoming milestones and a great partner in Genentech.

I would love to see the traditional summer slump knock this down to <$10, then I might reconsider.

I'm relying on JAV, AIS, and RPRX to take me through the summer, but I have been looking at KOOL (they have several major milestones coming up) as a short-term investment and VRUS, although I think there's no harm in waiting until Q4 for this one.